Skip to content
Nath Bio-Genes logo

Nath Bio-Genes (India)

NATHBIOGEN NSE
₹135.03 +2.36 (+1.78%)
P/E
6.64
View as Markdown
MCP
Close 4 Nov 2026 ₹135.03 −31.80 −19.1% 1Y
Start ₹166.83

Key Fundamentals

MicrocapConsumer GoodsFMCG

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
7.16%
Debt to Equity
0.20
EPS (TTM)
₹20.35
Book Value
₹358.06
Market Cap
—
P/E (TTM)
6.64
P/B
0.38
ROE
5.33%
Dividend Yield
1.51%
EBITDA
₹60.20 Cr
52W High
₹204.00
52W Low
₹126.15
Day Range
₹132.00 – ₹135.45
Volume
6,205

Peer Comparison

Fast Moving Consumer Goods › FMCG › Agricultural Products › Other Agricultural Products

Nath Bio-Genes peer comparison
LT Foods
₹410.1022.24₹14,281 Cr2.910.73%14.70%17.60%₹11,633 Cr₹640 Cr
KRBL
₹408.6512.33₹9,318 Cr1.501.12%11.70%15.20%₹6,009 Cr₹758 Cr
Gujarat Ambuja Exports
₹152.0916.77₹6,847 Cr1.940.20%9.72%12.50%₹6,032 Cr₹416 Cr
Kaveri Seed Company
₹680.2514.02₹3,469 Cr1.730.75%15.00%15.80%₹1,279 Cr₹249 Cr
Trualt Bioenergy
₹369.4520.27₹3,167 Cr1.960.00%8.38%10.40%₹2,050 Cr₹159 Cr
Amir Chand Jagdish Kumar (Exports)
₹222.5715.79₹2,241 Cr2.330.00%15.80%15.70%₹2,627 Cr₹132 Cr
GRM Overseas
₹92.9823.84₹1,926 Cr3.210.48%14.20%14.00%₹1,869 Cr₹77 Cr
Nath Bio-Genes (this company)
₹135.036.64₹255 Cr0.381.51%5.33%7.16%₹490 Cr₹39 Cr
Median 8 companies₹296.0116.28₹3,318 Cr1.950.61%12.95%14.60%₹2,338 Cr₹204 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

57 Good

Data confidence 98/100

Category scores

Quality
58
Good
Returns, margins, earnings quality 22% weight
Valuation
73
Strong
Cheap vs sector & own history 24% weight
Growth
67
Strong
Sales & profit trajectory 9% weight
Financial Health
57
Good
Solvency, leverage, coverage 9% weight
Momentum
31
Poor
Trend strength, vol-adjusted 12% weight
Ownership
49
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Stock is trading at 0.38 times its book value
  • Debtor days have improved from 116 to 87.0 days.

Weaknesses

4
  • Tax rate seems low
  • Company has a low return on equity of 5.88% over last 3 years.
  • Earnings include an other income of Rs.15.2 Cr.
  • Dividend payout has been low at 9.52% of profits over last 3 years

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish955
OscillatorsNeutral252
Moving AveragesStrong Bearish703

Key readings

RSI (14)
45.99
Neutral
MACD (12,26,9)
−3.03
Bullish
SMA (50)
143.19
Bearish
SMA (200)
154.20
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10YIrregular period
5YIrregular period
3Y+15.23%
1Y+33.58%
TTM+20.99%

Net profit

Net profit growth by window
10YIrregular period
5YIrregular period
3Y+6.27%
1Y+7.69%
TTM+18.18%

Operating cash flow

Operating cash flow growth by window
10YIrregular period
5YIrregular period
3YTurned negative
1YTurned negative
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10YIrregular period
5YIrregular period
3Y−6.14 pp
1Y−4.23 pp
TTM−0.37 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2012₹97.00 Cr
Mar 2013₹109 Cr
Mar 2022₹230 Cr
Mar 2023₹234 Cr
Mar 2024₹248 Cr
Mar 2025₹268 Cr
Mar 2026₹358 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2012₹9.00 Cr
Mar 2013₹12.00 Cr
Mar 2022−₹67.00 Cr
Mar 2023₹35.00 Cr
Mar 2024₹40.00 Cr
Mar 2025₹39.00 Cr
Mar 2026₹42.00 Cr

Quarterly Results

₹ Cr
NATHBIOGEN quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
235
23
32
43
244
32
37
52
284
44
66
52
328
Expenses
198
18
26
39
207
27
29
52
254
38
62
47
293
Operating Profit
37
5
6
4
37
5
8
0
29
6
4
4
35
OPM %
16%
22%
18%
9%
15%
15%
22%
0.8%
10%
14%
5%
9%
11%
Other Income
0
0
3
0.41
0
0
0
4
4
4
4
2.38
1.9
Interest
3
2
3
1
2
3
4
1
3
4
5
5
4
Depreciation
1
1
1
1
1
1
1
1
1
1
1
1
1
PBT
33.4
2
5
3
34
1
4
2
29
5
2
2
33
Tax %
1%
19%
17%
19%
1%
−3%
30%
30%
2%
12%
35%
100%
2%
Net Profit
33
2
4
3
33
1
3
1
28
5
2
0
32
EPS (₹)
17.59
0.79
2.02
1.38
17.55
0.58
1.39
0.78
14.88
2.54
0.84
−0.01
16.98

Profit & Loss

₹ Cr
NATHBIOGEN profit and loss, annual, ₹ crore
Particulars Mar 2012Mar 2013Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
97
109
230
234
248
268
358
490
Expenses
82
89
193
185
198
217
305
440
Operating Profit
15
20
37
49
50
51
53
49
OPM %
15%
18%
16%
21%
20%
19%
15%
10%
Other Income
1
1
−87
1
4
4.55
14
15
Interest
2
4
11
10
9
10.48
16
17
Depreciation
5
5
3
3
3
4
4
4
PBT
9
12
−63
36
42
41
46
43
Tax %
−1%
4%
6%
3%
5%
5%
10%
—
Net Profit
9
12
−67
35
40
39
42
39
EPS (₹)
5.75
7.34
−35.46
18.43
20.85
20.31
21.91
20.35
Div. Payout %
0%
0%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
11%
10%
10%
9%
—

Balance Sheet

₹ Cr
NATHBIOGEN balance sheet, annual, ₹ crore
Particulars Mar 2012Mar 2013Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
19
19
19
19
19
Reserves
30
41
523
554
591
625
661
Borrowings
11
19
93
105
110
123
138
Other Liabilities
63
82
105
114
160
259
278
Total Liabilities
120
158
739
793
880
1,026
1,097
Fixed Assets
21
38
245
244
249
250
249
CWIP
0
0
0
0
0
0
0
Investments
1
0
5
5
6
6
6
Other Assets
99
121
490
543
625
770
842
Total Assets
120
158
739
793
880
1,026
1,097

Cash Flow

₹ Cr
NATHBIOGEN cash flow, annual, ₹ crore
Particulars Mar 2012Mar 2013Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
—
—
17
38
75
18
−13
Investing
—
—
−20
−3
−27
−4
3
Financing
—
—
−22
−2
−8
−2
−4
Net Cash Flow
—
—
−25
34
39
11
−13
Free Cash Flow
—
—
16
36
48
10
−16
CFO/OP
—
—
54
80
150
37
−22

Ratios

NATHBIOGEN financial ratios, annual
Particulars Mar 2012Mar 2013Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
47
70
136
152
139
121
87
Inventory Days
587
667
—
4,388
—
—
—
Days Payable
146
239
—
586
—
—
—
Cash Conversion Cycle
487
499
136
3,954
139
121
87
Working Capital Days
79
64
427
415
342
321
314
ROCE %
—
24%
—
7%
7%
7%
7%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Nath Bio-Genes insights

64 extracted metrics across FY12–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 45.60%
  • Public 34.71%
  • Others 19.50%
  • FIIs 0.19%
  • DIIs 0.01%

13.78% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

  • Q1 FY27 concall · Jul 2026
    PPT
  • Q4 FY26 concall · May 2026
    Transcript PPT
  • Q3 FY26 concall · Jan 2026
    PPT
  • Q2 FY26 concall · Nov 2025
    Transcript PPT
  • Q1 FY26 concall · Jul 2025
    PPT

Frequently Asked Questions about Nath Bio-Genes (India)

What does Nath Bio-Genes (India) Ltd do?
Incorporated in 1993, Nath Bio-Genes Ltd is in the business of Production, Processing, and Marketing of Hybrid and GM Seeds
Where is Nath Bio-Genes (India) Ltd (NATHBIOGEN) listed?
Nath Bio-Genes (India) Ltd trades as NATHBIOGEN on the NSE and under code 537291 on the BSE.
Which sector does Nath Bio-Genes (India) Ltd belong to?
Nath Bio-Genes (India) Ltd is classified under the FMCG sector, in the Agricultural Products industry.
What is the PE ratio of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd trades at a PE ratio of 6.64 as of 4 Nov 2026, on earnings per share of ₹20.35, against a book value of ₹358.06 per share.
What is the 52-week high and low of Nath Bio-Genes (India) Ltd?
Over the last 52 weeks Nath Bio-Genes (India) Ltd has traded between ₹126.15 and ₹204 as of 4 Nov 2026.
Does Nath Bio-Genes (India) Ltd pay dividends?
Nath Bio-Genes (India) Ltd has a dividend yield of 1.51%.
What is the Return on Equity (ROE) of Nath Bio-Genes (India) Ltd?
Nath Bio-Genes (India) Ltd reported a return on equity of 5.33%. Its debt-to-equity ratio is 0.20.

Company Information

Incorporated in 1993, Nath Bio-Genes Ltd is in the business of Production, Processing, and Marketing of Hybrid and GM Seeds

Website nathbiogenes.com
CEO Mr. Satish Kagliwal
Employees 451
Listed 28 Jan 2014
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NATHBIOGEN.md for Nath Bio-Genes (India) Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Agri & Food Products stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month